ChemBriefSoriot Should Explain the Curious Case of AstraZeneca’s Non-Deal
AstraZeneca CEO Pascal Soriot faces scrutiny over rejecting a deal, maintaining a long-term R&D strategy over short-term acquisitions while targeting $80bn revenue by 2030.
theguardian · 2026-08-06 01:45